Can atenolol cause bronchospasm?

Can Atenolol Cause Bronchospasm?

Yes, atenolol can cause bronchospasm, though it is less likely to do so compared to non-selective beta-blockers because of its cardioselectivity. However, this cardioselectivity is dose-dependent and not absolute, meaning bronchospasm remains a real risk, particularly in patients with reactive airway disease.

Understanding the Risk

Atenolol is classified as a cardioselective (beta-1 selective) beta-blocker 1, 2, 3, 4, 5, 6. The major clinical guidelines consistently note that cardioselective beta-blockers like atenolol are "preferred in patients with bronchospastic airway disease requiring a beta blocker" 1, 2, 3, 4, 5, 6. This preference exists precisely because they carry lower risk of bronchospasm than non-selective agents—but the risk is not eliminated.

Evidence from FDA Drug Labeling

The FDA-approved labeling for atenolol explicitly lists bronchospasm as a documented adverse effect 7. In clinical trials:

• Wheeziness occurred in 3% of atenolol-treated patients (same as placebo in that particular study) 7
• In acute myocardial infarction studies, bronchospasm occurred in 1.2% of patients receiving atenolol 7
• The label specifically warns about respiratory adverse effects and notes that bronchospasm is a potential adverse effect 7
• In overdose situations, bronchospasm is listed as an expected effect requiring treatment with beta-2 agonists 7

Clinical Trial Evidence

Research studies demonstrate dose-dependent bronchospasm risk:

• A systematic review found that acute selective beta-blockers caused a mean FEV1 decline of -6.9%, with one in eight patients experiencing a ≥20% fall in FEV1 8
• Atenolol 100 mg induced long-lasting increases in airway resistance in patients with chronic obstructive lung disease, while lower doses (50 mg) showed neutral effects in most patients 9
• In asthmatic patients, atenolol 50 mg caused significant decreases in FEV1 and FVC 10
• A study in asthmatics with hypertension showed that all three doses of atenolol (50,100,200 mg) caused significantly less beta-2 blockade than propranolol but still caused measurable falls in FEV1 11

Clinical Implications and Risk Mitigation

When Bronchospasm Occurs

The bronchospasm induced by atenolol responds to beta-2 agonists, though the response may be attenuated 8, 10, 11. The systematic review showed that selective beta-blockers attenuated beta-2 agonist response by -10.2% (compared to -20.0% for non-selective agents) 8.

Dose-Response Relationship

A clear dose-response relationship exists—higher doses of atenolol carry greater bronchospasm risk 8, 9, 11. At 50 mg, atenolol may have neutral effects on airway resistance in many patients, but at 100 mg, significant bronchospasm becomes more likely 9.

Guideline Recommendations

The 2017 ACC/AHA Hypertension Guidelines state that cardioselective beta-blockers are "preferred in patients with bronchospastic airway disease requiring a beta blocker" 1, 2, 4, 5, 6, while non-selective agents like nadolol and propranolol should be "avoided in patients with reactive airways disease" 1, 2, 4, 5, 6.

The 2015 ACC/AHA/HRS SVT Guidelines list bronchospasm as a potential adverse effect of atenolol and include "reactive airway disease" as a precaution requiring careful use 12.

Common Pitfalls to Avoid

1. Don't assume cardioselectivity equals complete safety: Cardioselectivity is relative and dose-dependent, not absolute
2. Don't use high doses in patients with any reactive airway component: Start with the lowest effective dose (25-50 mg)
3. Don't confuse "preferred" with "safe": Atenolol is preferred over non-selective agents but still carries risk
4. Don't ignore individual patient variability: Some patients are more sensitive—6 of 12 patients in one study showed increased airway resistance even at lower doses 9

Bottom Line

Atenolol causes bronchospasm less frequently than non-selective beta-blockers but the risk is real and documented 7, 8. In patients with asthma or COPD who absolutely require beta-blockade, use the lowest effective dose of atenolol (starting at 25-50 mg), ensure beta-2 agonist rescue therapy is available, and monitor closely for respiratory symptoms 1, 8, 11.